Perrigo option to buy?
This article was originally published in The Tan Sheet
OTC generic firm files a schedule Form 13D with the Securities & Exchange Commission regarding an option to buy Rx generic drug manufacturer Lannett Company, Perrigo announces Feb. 13. The Allegan, Mich.-based firm was granted "an irrevocable option to acquire 13,581,629 share of Lannett stock, representing approximately 67% of Lannett's outstanding common shares," release states; the option expires Aug. 6. If agreed upon, Perrigo will pay Lannett Chairman & CEO William Farber $197.8 mil. ($14.56 per share). Perrigo President & CEO David Gibbons said the potential purchase is in line with the firm's "previously announced strategy to enter the generic drug market"...
You may also be interested in...
Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.
Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.
Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.